Adderall Refill Appointment: Essential Assessment and Management Protocol
For an Adderall refill appointment, you must systematically assess treatment response, monitor for side effects and cardiovascular changes, screen for substance misuse/diversion risk, and verify ongoing ADHD symptom control before authorizing the refill.
Pre-Refill Assessment Checklist
1. Treatment Response Evaluation
Assess target ADHD symptoms using standardized rating scales 1:
- For adults: obtain self-ratings using validated instruments (Adult ADHD Self-Report Scale or Conners Adult ADHD Rating Scale) 1
- Document functional improvement in at least two settings (work/school AND home/social) 1
- Ask specifically: "Are you still experiencing difficulty with attention, impulsivity, or hyperactivity that interferes with your daily functioning?"
Evaluate medication adherence 1:
- Review prescription fill history via prescription drug monitoring program (PDMP)
- Ask: "How many pills do you have left?" and calculate if usage matches prescribed dosing
- Inquire about missed doses and reasons
2. Side Effects Monitoring (Required at Every Visit)
Systematically ask about these specific side effects 1:
- Insomnia or sleep disturbances
- Decreased appetite/anorexia
- Headaches
- Stomach aches
- Social withdrawal
- Tics or involuntary movements
- Jitteriness/nervousness
- Irritability when medication wears off
Objective measurements required 1:
- Weight: Document at every visit to objectively assess appetite suppression 1
- Blood pressure and pulse: Check quarterly in adults 1; monitor for increases >5-15% above baseline 2
- Height (if child/adolescent): Monitor for growth attenuation, which averages 1-2 cm reduction from predicted adult height 2
3. Cardiovascular Safety Assessment
At baseline and ongoing 1:
- Blood pressure and pulse monitoring (quarterly minimum for adults)
- Ask about: chest pain, palpitations, syncope, exercise intolerance
- Review for new cardiovascular symptoms since last visit
Do NOT routinely order ECGs unless cardiac risk factors are present 3.
4. Substance Misuse and Diversion Screening
Critical questions to ask 4, 5:
- "Has anyone asked you for your medication or have you shared/sold any pills?"
- "Are you taking more than prescribed or taking it differently than directed?"
- "Are you using alcohol or other substances?" (obtain detailed drug/alcohol history) 1
- Consider urine drug screen if concerned about concurrent substance use 1
Review PDMP for:
- Early refills
- Multiple prescribers
- Concurrent controlled substances from other providers
Implement controlled substance agreement for ongoing monitoring 4.
5. Dose Optimization Assessment
If symptoms are not adequately controlled 1:
- Current dose may be suboptimal—stimulants are often underdosed in practice 6
- For immediate-release amphetamine salts: increase by 2.5-5 mg increments weekly 1
- Maximum FDA-approved dose: 40 mg/day for amphetamines 1, 7
- However, clinical practice may occasionally exceed these limits when titrated carefully based on response and tolerability 6, 8
If previously effective dose is losing efficacy 9:
- Consider tolerance development (occurs in 2.7-24.7% of patients)
- Options: switch to different stimulant formulation, implement drug holidays, or reassess diagnosis
- Ensure compliance first before assuming tolerance
6. Comorbidity Assessment
Screen for new or worsening psychiatric conditions 1:
- Depression or mood instability
- Anxiety symptoms (note: stimulants can be used with comorbid anxiety) 1, 10
- Psychotic symptoms (absolute contraindication—discontinue immediately) 1
- Substance use disorders
7. Documentation Requirements
Before authorizing refill, document 1:
- Current ADHD symptom severity and functional impairment
- Medication adherence
- Side effects present/absent
- Vital signs (BP, pulse, weight)
- PDMP review findings
- Justification for current dose
- Plan for next follow-up
Refill Decision Algorithm
AUTHORIZE REFILL if:
- ADHD symptoms remain present and impairing
- Current dose provides benefit without intolerable side effects
- No evidence of misuse/diversion
- Vital signs acceptable (BP/pulse increases <15% from baseline)
- PDMP shows appropriate usage pattern
DO NOT REFILL if:
- Evidence of diversion or misuse
- Development of psychotic symptoms 1
- Uncontrolled hypertension or new cardiovascular symptoms 1
- Patient lost to follow-up >3 months without contact 1
- Pregnancy (relative contraindication—requires risk-benefit discussion)
MODIFY TREATMENT if:
- Inadequate symptom control: increase dose in 2.5-5 mg increments 1
- Intolerable side effects: reduce dose or switch formulation 1
- Tolerance suspected: consider drug holiday or switch stimulant type 9
- New comorbid substance use: consider switching to non-stimulant (atomoxetine) 11
Follow-Up Schedule
- During dose titration: Weekly contact (can be by phone) 1
- After stabilization: Monthly until symptoms stabilized 1
- Maintenance phase: Every 1-3 months depending on stability, comorbidities, and adherence concerns 1
Critical Pitfalls to Avoid
- Failing to check PDMP before every refill—this is essential for detecting diversion 4
- Not weighing the patient—weight loss is an objective marker of appetite suppression 1
- Assuming tolerance without verifying adherence first 9
- Stopping medication if tics emerge—controlled trials show stimulants don't worsen tics in most patients 1
- Underdosing—many patients require doses at the higher end of the FDA range for optimal response 6, 8
- Refilling without documented functional impairment—ADHD must cause moderate-to-severe impairment in ≥2 settings to justify continued treatment 1